Related Experiment Videos
Efficacy and side effects of methylphenidate for poststroke depression.
L W Lazarus1, D R Winemiller, V R Lingam
1Rush-Presbyterian-St. Luke's Medical Center, Chicago, Ill. 60612.
The Journal of Clinical Psychiatry
|December 1, 1992
Summary
Methylphenidate shows promise for treating poststroke depression in elderly patients. This study found 80% of participants experienced significant symptom improvement with minimal side effects, suggesting it as a safe and effective option.
Area of Science:
- Neurology
- Psychiatry
- Geriatrics
Background:
- Poststroke depression (PSD) significantly hinders recovery and increases patient/family distress.
- Limited research exists on pharmacological interventions for PSD.
- This study investigates methylphenidate for elderly PSD patients.
Purpose of the Study:
- To evaluate the efficacy and safety of methylphenidate in treating major depression in elderly stroke survivors.
- To assess the side effect profile of methylphenidate in this specific population.
Main Methods:
- A 3-week open-label trial of methylphenidate was conducted.
- Ten elderly subjects (mean age 73.2 years) meeting DSM-III-R depression criteria were enrolled.
- Participants were selected from stroke rehabilitation patients referred for psychiatric evaluation.
Main Results:
- 80% (8 of 10) of subjects demonstrated a full or partial response to methylphenidate.
- Response was measured using the Hamilton Rating Scale for Depression.
- The incidence of significant side effects was low, with no discontinuations due to adverse events.
Conclusions:
- Methylphenidate appears to be a safe and effective treatment for poststroke depression in the elderly.
- Further research, including placebo-controlled trials and comparisons with standard antidepressants, is warranted.